RESMED INC shareholders Q4 2021

RESMED INC's ticker is RMD and the CUSIP is 761152107. A total of 714 filers reported holding RESMED INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.2%.

RESMED INC shareholders Q4 2021
NameSharesValueWeighting ↓
FOX RUN MANAGEMENT, L.L.C. 2,083$543,0000.32%
Andra AP-fonden 59,500$15,499,0000.32%
OPSEU Pension Plan Trust Fund 5,369$1,380,0000.31%
AMERICAN NATIONAL BANK 6,127$1,596,0000.31%
Campbell & CO Investment Adviser LLC 3,423$892,0000.31%
Rockefeller Capital Management L.P. 248,764$64,796,0000.30%
Aquatic Capital Management LLC 600$156,0000.30%
Congress Wealth Management LLC / DE / 57,622$15,009,0000.30%
Oak Thistle LLC 1,474$384,0000.30%
Enlightenment Research, LLC 800$208,0000.30%
Bridgewater Associates 187,402$48,814,0000.28%
NICHOLAS COMPANY, INC. 65,920$17,171,0000.28%
NuWave Investment Management, LLC 944$246,0000.28%
Engineers Gate Manager LP 23,471$6,114,0000.28%
FORA Capital, LLC 2,698$703,0000.27%
L. Roy Papp & Associates, LLP 9,050$2,357,0000.27%
Edgestream Partners, L.P. 16,363$4,262,0000.27%
BREITER CAPITAL MANAGEMENT INC 2,031$529,0000.26%
Oak Harvest Investment Services 3,969$1,034,0000.26%
PERSONAL CFO SOLUTIONS, LLC 5,209$1,357,0000.25%
About RESMED INC

ResMed Inc. is a global leader in the development, manufacturing, and distribution of medical equipment for the treatment of sleep apnea and other respiratory disorders. The company has been in operation for over 30 years and has a strong reputation for innovation and quality.

ResMed's products include continuous positive airway pressure (CPAP) machines, masks, and accessories. These products are designed to help patients with sleep apnea breathe more easily and get a better night's sleep. The company's products are sold in over 120 countries worldwide, and ResMed has a strong presence in both the home healthcare and hospital markets.

One of the key strengths of ResMed is its commitment to research and development. The company invests heavily in R&D, and has a team of over 1,000 engineers and scientists working to develop new products and improve existing ones. This focus on innovation has helped ResMed to maintain its position as a market leader in the sleep apnea treatment market.

In addition to its strong product portfolio, ResMed has a solid financial position. The company has consistently delivered strong financial results, with revenue and earnings growth outpacing the industry average. ResMed's strong financial position has allowed it to invest in new product development and expand its global footprint.

Overall, ResMed is a well-established and respected company in the medical equipment industry. With a strong focus on innovation and a solid financial position, the company is well-positioned for continued growth and success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists RESMED INC's shareholders in Q4 2021. To view RESMED INC's shareholder history, click here.